These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 12758190)

  • 1. From multidrug-resistant tuberculosis to DOTS expansion and beyond: making the most of a paradigm shift.
    Kim JY; Mukherjee JS; Rich ML; Mate K; Bayona J; Becerra MC
    Tuberculosis (Edinb); 2003; 83(1-3):59-65. PubMed ID: 12758190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DOTS-Plus for multidrug-resistant tuberculosis in the Philippines: global assistance urgently needed.
    Tupasi TE; Quelapio MI; Orillaza RB; Alcantara C; Mira NR; Abeleda MR; Belen VT; Arnisto NM; Rivera AB; Grimaldo ER; Derilo JO; Dimarucut W; Arabit M; Urboda D
    Tuberculosis (Edinb); 2003; 83(1-3):52-8. PubMed ID: 12758189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Multiple drug resistance: a threat for tuberculosis control].
    Cardoso EM
    Rev Panam Salud Publica; 2004 Jul; 16(1):68-73. PubMed ID: 15333267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies.
    Kibret KT; Moges Y; Memiah P; Biadgilign S
    Infect Dis Poverty; 2017 Jan; 6(1):7. PubMed ID: 28093078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Multidrug resistant tuberculosis in Romania in the last years (2004-2007)--an extremely important social phenomenon].
    Marica C; Didilescu C; Chiotan D; Galie N; Tănăsescu M; Popescu-Hagen M; Popa M
    Pneumologia; 2008; 57(4):195-200. PubMed ID: 19186681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Directly observed therapy, short-course: the best way to prevent multidrug-resistant tuberculosis.
    Yew WW
    Chemotherapy; 1999; 45 Suppl 2():26-33. PubMed ID: 10449895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.
    Pablos-Mendez A; Gowda DK; Frieden TR
    Bull World Health Organ; 2002; 80(6):489-95; discussion 495-500. PubMed ID: 12132008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug resistant tuberculosis].
    Zwolska Z; Augustynowicz-Kopeć E
    Pol Merkur Lekarski; 2011 May; 30(179):362-6. PubMed ID: 21675144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A UK-based resource to support the monitoring and safe use of anti-TB drugs and second-line treatment of multidrug-resistant TB.
    Potter JL; Capstick T; Ricketts WM; Whitehead N; Kon OM
    Thorax; 2015 Mar; 70(3):297-8. PubMed ID: 24928813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protocol for the management of newly diagnosed cases of tuberculosis.
    Katiyar SK; Katiyar S
    Indian J Tuberc; 2019 Oct; 66(4):507-515. PubMed ID: 31813442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decline in rates of acquired multidrug-resistant tuberculosis after implementation of the directly observed therapy, short course (DOTS) and DOTS-Plus programmes in Taiwan.
    Chien JY; Lai CC; Tan CK; Chien ST; Yu CJ; Hsueh PR
    J Antimicrob Chemother; 2013 Aug; 68(8):1910-6. PubMed ID: 23580558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors contributing to the high prevalence of multidrug-resistant tuberculosis among previously treated patients: a case-control study from China.
    Wang K; Chen S; Wang X; Zhong J; Wang X; Huai P; Wu L; Wang L; Jiang S; Li J; Peng Y; Yao H; Ma W
    Microb Drug Resist; 2014 Aug; 20(4):294-300. PubMed ID: 24328894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of multidrug-resistant tuberculosis].
    Tritar F; Daghfous H; Ben Saad S; Slim-Saidi L
    Rev Pneumol Clin; 2015; 71(2-3):130-9. PubMed ID: 25153927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond DOtS: avenues ahead in the management of tuberculosis.
    Chaudhury RR; Thatte U
    Natl Med J India; 2003; 16(6):321-7. PubMed ID: 14765625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?
    Gupta R; Raviglione MC; Espinal MA
    Int J Tuberc Lung Dis; 2001 Dec; 5(12):1078-9. PubMed ID: 11769764
    [No Abstract]   [Full Text] [Related]  

  • 16. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus.
    Kam KM; Yip CW
    Int J Tuberc Lung Dis; 2004 Jun; 8(6):760-6. PubMed ID: 15182147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of drug resistance under the DOTS strategy in Hyderabad, South India, 2001-2003.
    Anuradha B; Aparna S; Hari Sai Priya V; Vijaya Lakshmi V; Akbar Y; Suman Latha G; Murthy KJ
    Int J Tuberc Lung Dis; 2006 Jan; 10(1):58-62. PubMed ID: 16466038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment and implications of multidrug-resistant tuberculosis for the 21st century.
    Iseman MD
    Chemotherapy; 1999; 45 Suppl 2():34-40. PubMed ID: 10449896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment outcome cohort analysis in an integrated DOTS and DOTS-Plus TB program in Latvia.
    Riekstina V; Leimane V; Holtz TH; Leimans J; Wells CD
    Int J Tuberc Lung Dis; 2007 May; 11(5):585-7. PubMed ID: 17439686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?
    Ragonnet R; Trauer JM; Denholm JT; Marais BJ; McBryde ES
    BMC Infect Dis; 2017 Jan; 17(1):36. PubMed ID: 28061832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.